The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

Start Date15 Aug 2024

Sponsor / Collaborator

University of Iowa

NCT03816488

/ WithdrawnPhase 1IIT

Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control - A Placebo-Controlled Internal Feasibility Trial

Hypothesis: In surgical patients with type 2 diabetes, taking either metformin or salsalate on the morning of surgery will reduce the incidence of hyperglycemia, inflammation and even surgical site infections, without any obvious patient risk relative to patients given a placebo control.
Anesthesia and surgery induce a number of metabolic disturbances, particularly among patients with type 2 diabetes (T2D). This includes altered glucose metabolism and hyperglycemia, which is associated with significant morbidity and mortality, including an increase in surgical site infections (SSI). Although insulin protocols can reduce blood glucose levels in hyperglycemic surgical patients, leading to reduced SSI, this has caused severe hypoglycemia in a number of patients. Instead, the use of simple and effective interventions, such as continuing metformin on the day of surgery, could represent an important step toward reducing the incidence of these morbid outcomes while improving glucose control. Alternatively, salsalate, a non-acetylated dimer of salicylic acid, has also emerged as a novel glucose-lowering medication that also possesses important anti-pyretic and anti-inflammatory properties and could prove equally effective.These refinements may also reduce SSI and inflammation. If the proposed pilot trial, to continue metformin, or take salsalate, peri-operatively, is as safe and easy as the investigators anticipate it will allow for the planning of a future definitive randomized clinical trial. The aims of this pilot trial are to assess the feasibility of safely continuing metformin, or taking salsalate on the day of surgery, with the goal of reducing the incidence of hyperglycemic events. This includes assessing our ability to recruit patients, adhere to the proposed study protocol, assess workload,and measure the desired outcomes, all of which are crucial for the planning of a subsequent clinical trial.

Start Date01 Dec 2023

Sponsor / Collaborator

McMaster University

[+1]

NCT05169060

/ Active, not recruitingPhase 1/2IIT

Effects of Fish Oil ± Salsalate on the Omega-3 Index and the Circulating Lipodome of Omega-3 Polyunsaturated Fatty Acid Metabolites in Patients With Type 2 Diabetes and Diabetic Neuropathy

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mortality, and high health care costs. Due to the complex structure and anatomy of the peripheral nervous system, DPN presents with a very broad spectrum of clinical symptoms and deficits, including severe pain, sensory deficits, foot ulcers and amputations. Presently there is no treatment for DPN and even with good blood glucose control DPN develops especially in patients with type 2 diabetes. There is a need to identify effective interventions for DPN. Preclinical studies have provided evidence that the combination of fish oil and salsalate is an effective treatment of DPN. The human subject study to be performed will examine the effect of fish oil with and without salsalate on the blood lipid profile and circulating metabolites of omega-3 polyunsaturated fatty acids (PUFA). Fish oil is an excellent source for the nutrition dependent omega-3 PUFA, primarily eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid (DHA; 22:6). These fatty acids are the source of anti-inflammatory metabolites known as resolvin, neuroprotectin and maresin. Preclinical studies have also demonstrated that the metabolites of EPA and DHA are neuroprotective. Furthermore, when fish oil is combined with salsalate the production of these metabolites is increased in vivo. Thus, the investigators hypothesize that fish oil and salsalate will be an effective therapy of DPN. However, prior to doing a formal study of the effect of fish oil + salsalate on DPN there is a need to learn more about what concentration combination will provide the most efficacious effect on the omega-3 index (defined as the sum of EPA and DHA, as a percentage of total fatty acids in red blood cells) and that will safely increase the production of the anti-inflammatory metabolites. These studies will be performed at two sites the University of Iowa (Dr. Yorek) and University of Michigan (Dr. Pop-Busui) by treating human subjects with type 2 diabetes and DPN with either 2g or 4g of fish oil per day (capsules) for 4 months and then adding salsalate 1.5 g or 3g per day (tablets) to the fish oil treatments for an additional 2 months. At baseline and after treatment with fish oil alone and after treatment with the combination of fish oil and salsalate the omega-3 index and levels of circulating omega-3 PUFA metabolites will be determined as primary endpoints. Secondary endpoints will include determination of circulatory inflammatory markers and non-invasive measurements for DPN. The risks to subjects are minimal and are very reasonable in relation to the importance of the knowledge to be gained.

Start Date12 Jun 2023

Sponsor / Collaborator

University of Iowa

[+3]

100 Clinical Results associated with Salsalate

100 Translational Medicine associated with Salsalate

100 Patents (Medical) associated with Salsalate

344

Literatures (Medical) associated with Salsalate

01 Apr 2026·INFLAMMOPHARMACOLOGY

Unrevealing possible mechanism of Riluzole, Salsalate and Nimodipine in Alzheimer’s disease: multi-target network pharmacological perspective

Article

Author: Mehta, Dinesh Kumar ; Das, Rina ; Roy, Kishor Kumar

BACKGROUND: Riluzole (RLZ), a benzothiazole, maintains glutamatergic homeostasis, salsalate (SLS) a NSAIDs suppresses NF-κB, and Nimodipine (NMD) blocks of calcium channels, addressing Alzheimer’s Diseases (AD) related excitotoxic, inflammatory, metabolic, and neurological disorders etc. has mapped drug-target-disease interactions and examined mechanism of RLZ, SLS, and NMD on AD. AIM: This study aims to employ network pharmacology approach to investigate the possible therapeutic mechanism of RLZ, SLS, and NMD in AD. MATERIALS AND METHODS: Developed a PPI network to find the main therapeutic targets of RLZ, SLS, and NMD against AD. Got canonical SMILES (Simplified Molecular Input Line Entry System) from PubChem and used several databases (SwissTargetPrediction, DisGeNET, STRING, DAVID, ShinyGO, ADMETlab 3.0, MolSoft, ProTox 3.0) to find AD-associated genes, pharmacokinetic/toxicity features, and to do functional enrichment. DrugBank, Lexicomp, DailyMed, and Medscape to analyse DDIs. RESULTS: RLZ, SLS, and NMD share 25 targets with AD and share KEGG pathways like “Alzheimer’s disease”, “neurodegeneration multiple diseases”, “insulin-resistance”, etc. with hub genes like CASP3, STAT3, APP, GSK3B, ACE, NOS3, MAPT, IGF1R, ACHE, and PPARA. RLZ primarily targeted nuclear and membrane receptors with high blood-brain barrier penetration, SLS targeted oxidoreductases and inflammatory/tau targets with a broad safety margin, and NMD targeted G-protein coupled receptors and calcium/vascular nodes despite a complex transporter-CYP interactome. DDI analysis showed moderate interactions between the NMD and SLS according to DrugBank and other 3 data base shown no significant interaction. CONCLUSIONS: RLZ, SLS, and NMD target multiple pathogenic pathways to regulate AD. Combining RLZ, SLS, and NMD may reduce excitotoxicity, neuroinflammation, metabolic dysfunction, and vascular injury in AD, suggesting promise for additional in-vivo and clinical trials.

01 Dec 2025·COMPUTATIONAL BIOLOGY AND CHEMISTRY

In silico study of salicylic acid derivatives as inhibitors of Ebola proteins through molecular docking

Article

Author: Rahimi, Rezvan ; Abnosi, Mohammad Hossein ; Solimannejad, Mohammad

The Zaire Ebola virus is a highly virulent RNA virus that causes severe hemorrhagic fever in humans and nonhuman primates, with no effective treatments currently available. This study evaluates the inhibitory potential of six salicylic acid derivatives including aspirin, diflunisal, fendosal, fosfosal, salicylic acid, and salsalate; against three key Ebola virus receptor proteins through in-silico analysis. Molecular docking techniques have employed to model the interactions between these derivatives and the viral proteins VP24, VP35, and VP40. The results revealed that the salicylic acid derivatives demonstrated significantly stronger binding affinities to the VP35 receptor compared to other receptor proteins studied. Among the derivatives screened, those targeting the VP35 protein exhibited superior binding energy, glide energy, glide E_model, glide E_vdw, and glide ligand efficiency, alongside the lowest RMSD values. These findings suggest that salicylic acid derivatives hold promise as potential anti-Ebola therapies and warrant further investigation in clinical trials.

22 Aug 2025·Endocrine Metabolic & Immune Disorders-Drug Targets

Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative Analysis via Network Pharmacology, Mendelian Randomization, Molecular Docking, and In Vitro Validation

Article

Author: Xueke Lu ; Wenbo Gong ; Siying Weng

Introduction::

Jiangtang Decoction (JTD) demonstrates notable efficacy in managing Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). This study aimed to elucidate JTD';s causal targets and therapeutic mechanisms by integrating network pharmacology, Summary-data Mendelian Randomization (SMR), and molecular docking, complemented by in vitro validation.

Materials and Methods::

JTD';s targets were cross-matched with genes associated with T2DM or NAFLD. SMR and co-localization analyses, utilizing eQTL and pQTL data, identified causal signals for each disease and their shared counterparts. GO/KEGG enrichment analyses were performed on these shared signals. Molecular docking assessed binding interactions. In vitro experiments, including ELISA (Enzyme-linked immunosorbent assay) and lipid staining, evaluated JTD';s hypoglycemic/hypolipidemic effects, while PCR/immunofluorescence validated key molecular predictions in High-Glucose and High-Lipid (HGHL)-induced HepG2 cells.

Results::

Initial network pharmacology identified 1107 JTD targets for T2DM and 1126 for NAFLD. SMR analyses revealed 78 eQTLs and 67 pQTLs for T2DM, and 40 eQTLs and 38 pQTLs for NAFLD. Eight shared causal genetic signals were identified: ADAMTS4, ALDH2, GLO1, CDH1, PDHB, PRKAB1, TCF4, and EP300. In vitro, JTD significantly attenuated hepatic gluconeogenesis and lipid deposition, downregulated IL-1β, and notably restored PRKAB1 expression in HepG2 cells treated with HGHL.

Discussion::

Enrichment analysis revealed shared processes, including membrane microdomains, oxidoreductase activity, and responses to nutrient and oxygen levels. PRKAB1 exhibited a strong binding affinity with the JTD component Salsalate.

Conclusion::

This study identified eight genes that are genetically predicted to be causal for the therapeutic effects of JTD on both T2DM and NAFLD, thereby establishing a genetic link between the conditions. These targets and associated pathways illuminate common underlying mechanisms, supporting JTD';s potential for integrated treatment strategies and providing a basis for further investigation.

News (Medical) associated with Salsalate

30 Apr 2026

·www.biospace.com

YARAL Pharma Launches 15-Count Diclofenac Epolamine Topical System 1.3%, Offering Pharmacists a Flexible, Space-Saving Option

Compact packaging helps simplify storage, ease inventory concerns, and make daily pharmacy operations more manageable PARSIPPANY, N.J.--(BUSINESS WIRE)-- YARAL Pharma Inc. (YARAL Pharma), the rapidly growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), today announced that its Diclofenac Epolamine Topical System 1.3% , the authorized generic of Flector ® (diclofenac epolamine) topical system 1.3%, is now available in a 15-count carton. Designed to meet the operational needs of today’s pharmacies, the new 15-count configuration helps pharmacists reduce clutter, optimize storage space, and manage inventory with greater flexibility, while continuing to provide patients with the same trusted therapy. “As pharmacy shelves, drawers, and bins become increasingly crowded, thoughtful packaging makes a difference,” said Stephen Beckman, CEO of YARAL Pharma. “Our 15-count Diclofenac Epolamine Topical System delivers the same product patients and pharmacists rely on, now in a smaller footprint that can save up to 50% of shelf space compared to the 30-count carton.” With its compact size and practical design, the 15-count Diclofenac Epolamine Topical System offers several advantages for pharmacies: Space-Saving & Organized Storage – A smaller carton height reduces clutter, simplifies stacking, and fits easily into limited shelf, drawer, or bin space. Streamlined Workflow – Easier to locate, stock, and access during daily operations, helping reduce time spent managing inventory. Flexible Inventory Management – The smaller pack size supports more efficient stocking, helps prevent over-ordering, and allows pharmacies to better match inventory to demand – especially when space is limited. Product Information YARAL Pharma’s Diclofenac Epolamine Topical System 1.3% is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. Product NDC Number Dimensions 15-Count (3 envelopes per carton) * NDC 82347-0405-6 8.25” x 6.124” x 1.375” 30-Count (6 envelopes per carton) * NDC 82347-0405-5 8.25” x 6.124” x 2.375” *Packaged 5 topical systems per envelope YARAL Pharma’s Diclofenac Epolamine Topical System 1.3% 15-count is now available. For more information, email info@yaralpharma.com or call (866) 218-9009. USE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is prescription medication that is applied to the skin to treat acute pain from minor strains, sprains, and contusions (bruises) in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% contains diclofenac epolamine (a non-steroidal anti-inflammatory drug or NSAID). IMPORTANT SAFETY INFORMATION What is the most important information I should know about DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%? DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drugs (NSAID). NSAIDs can cause an increased risk of heart attack or stroke that can lead to death. This may happen early in treatment and may increase with increasing doses of NSAIDs and with longer use of NSAIDs. Do not take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% right before or after a heart surgery called “coronary artery bypass graft” (CABG). Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. NSAIDs can cause an increased risk of bleeding, ulcers, and tears (perforation) of the esophagus, stomach, and intestines: at any time during treatment without warning may cause death. The risk of getting an ulcer or bleeding increases with: a history of stomach ulcers, or stomach or intestinal bleeding with the use of NSAIDs taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs”, or “SNRIs” increasing doses of NSAIDs longer use of NSAIDs smoking drinking alcohol older age poor health advanced liver disease bleeding problems NSAIDS should only be used: exactly as prescribed at the lowest dose possible for your treatment for the shortest time needed Who should not take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%? Do NOT take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% if you have a known hypersensitivity reaction to diclofenac or any component of the drug product. Do NOT take DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% if you have had an asthma attack, hives, or other allergic reactions to aspirin or any other NSAID medicine. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% should never be used right before or after heart bypass surgery. Do NOT apply DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% to open wounds, cuts, burns, infected, or damaged skin. Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have high blood pressure have asthma are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after 30 weeks of pregnancy. are breastfeeding or plan to breast feed. Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins, or herbal supplements . NSAIDs and some other medicines can interact with each other and cause serious side effects. Avoid using DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% with other NSAIDs or salicylates (e.g., diflunisal, salsalate). NSAIDs may be available as over-the-counter medications for treatment of colds, fever, or insomnia. Do not start taking any new medicine without talking with your healthcare provider first. Especially tell your doctor if you take: aspirin--Do not use low dose aspirin with DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% until you talk to your healthcare provider. any anticoagulant medicine such as warfarin steroid medications including corticosteroids antidepressant medicines including “SSRIs” or “SNRIs” Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. What are the possible side effects of NSAIDs? See “What is the most important information I should know about DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3%?” NSAIDs can cause serious side effects, including: new or worse high blood pressure heart failure liver problems including liver failure kidney problems including kidney failure low red blood cells (anemia) life-threatening skin reactions life-threatening allergic reactions Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness The most common side effects of DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% were itching and nausea in adults, and headache and itching in pediatric patients. Get emergency help right away if you get any of the following symptoms: shortness of breath or trouble breathing, slurred speech, chest pain, swelling of the face or throat, or weakness in one part or side of your body. Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: nausea vomit blood more tired or weaker than usual there is blood in your bowel movement, or it is black and sticky like tar diarrhea itching unusual weight gain your skin or eyes look yellow skin rash or blisters with fever indigestion or stomach pain swelling of the arms, legs, hands, and feet flu-like symptoms If you take too much of your NSAID, call your healthcare provider or get medical help right away. These are not all the possible side effects of DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% or NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs or for advice about side effects. You are encouraged to report side effects to YARAL Pharma Professional Information Service at 1-866-218-9009 or FDA at 1-800-FDA-1088 or . Please see the Full Prescribing Information, including BOXED WARNING and Patient Information at About YARAL Pharma YARAL Pharma Inc. (Parsippany, N.J.) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the U.S. market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit or contact info@yaralpharma.com or 866-218-9009. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40 th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,500 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. Flector ® is a registered trademark of IBSA Institut Biochimique S.A. YPM-1500-EN-v1 Contacts Media Daina Basile Kovak-Likly Communications dbasile@klcpr.com

Acquisition

100 Deals associated with Salsalate

External Link

KEGG	Wiki	ATC	Drug Bank
D00428	Salsalate	N02BA06	DB01399

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	China	Jiuquan Dadeli Pharmaceutical Co Ltd	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Preclinical	United States	J & D Pharmaceuticals LLC	17 Nov 2025
Polycystic Kidney, Autosomal Dominant	Preclinical	United States	J & D Pharmaceuticals LLC	05 Sep 2025
Hutchinson-Gilford progeria syndrome	Preclinical	United States	J & D Pharmaceuticals LLC	03 Jul 2024
Laminopathies	Preclinical	United States	J & D Pharmaceuticals LLC	03 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03229408 (TIN-PCOS-AOD, CTgov)	Phase 2	Polyendocrine Metabolic Ovarian Syndrome \| Inflammation	60	Salsalate (Experimental: Salsalate-Treated PCOS)	mgxjpqzxvm(istcakfphj) = jtotfadycs nzymqhpyug (rfodawurja, 717) View more	-	10 Jun 2025
				Placebo (Placebo Comparator: Placebo-Treated PCOS)	mgxjpqzxvm(istcakfphj) = lxyellovyn nzymqhpyug (rfodawurja, 539) View more
NCT03482440 (CTgov)	Early Phase 1	Pregnancy \| Coronary microvascular dysfunction \| Inflammation ... View more	24	Placebo Oral Tablet (Placebo)	qeiyfrarst(apygwibukz) = nknnthxoid urdgkloeed (xbdgqinvpw, maaosofbkt - aspgxcjnss) View more	-	03 Jun 2025
				Salsalate Oral Tablet (Salsalate)	qeiyfrarst(apygwibukz) = ebhetngpca urdgkloeed (xbdgqinvpw, boafcwezhh - zmyvlglnrx) View more
NCT02936843 (TINSAL-T1DN, CTgov)	Phase 2/3	Diabetes Mellitus, Type 1 \| Inflammation \| Diabetic Neuropathies	61	Salsalate (Salsalate)	ahupftcdeg(vayauewwgs) = hqsodhmnud cdcdwtnzlj (uucvtgizip, 57) View more	-	16 May 2025
				PLACEBO (Comparator)	ahupftcdeg(vayauewwgs) = ymbjuoephu cdcdwtnzlj (uucvtgizip, 55) View more
NCT02936843 (TINSAL-T1DN, ADA2024)	Phase 2/3	Diabetic Neuropathies	-	Salsalate 3 grams daily	mjcnlagjyp(wgrkrzpeqr) = No significant differences were found in the primary outcome after 12 months eltuyciluv (jgowlvloch )	Positive	14 Jun 2024
				Placebo
NCT01977417 (INCITE, CTgov)	Phase 2	Prediabetic State \| Inflammation \| Obesity ... View more	21	Salsalate (Salsalate)	vjcwnfurob(zmgrcwnuka) = rxgkqdjlzy hkptrqvxcd (vybjvrtxpj, 4.35) View more	-	11 Sep 2023
				Placebo (Placebo)	vjcwnfurob(zmgrcwnuka) = vojhhnzjwn hkptrqvxcd (vybjvrtxpj, 6.43) View more
NCT04146038 (CTgov)	Phase 2	Recurrent Acute Leukemia \| Myeloproliferative Disorders \| Chronic Myelomonocytic Leukemia ... View more	5	Venetoclax+Decitabine+Salsalate+Azacitidine	midvkgylvj = wicwtcdxsc dkihmyqawh (fcvmhomimf, zdtfrxvtwp - ontfzsuvhs) View more	-	24 May 2023
NCT00837590 (CTgov)	Phase 1	Prediabetic State \| Inflammation \| Obesity	16	Acute Salsalate (Acute Salsalate)	iivdesvwff(kpecxofbcj) = goqomytdyd peaogfxkhk (yevedqxlfr, 2.3) View more	-	01 Aug 2019
				Chronic salsalate (Chronic Salsalate - Obese)	iivdesvwff(kpecxofbcj) = bezsrgupnx peaogfxkhk (yevedqxlfr, 1.7) View more
NCT01578486 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	17	salsalate	vqxrufwdim(mtzitthtef) = kbwgptkqpa tsrkxaarhr (ixhtdnztss, 11.4) View more	-	08 May 2018
NCT00624923 (TINSAL-CVD, CTgov)	Phase 2/3	Coronary Artery Disease \| Inflammation \| Overweight ... View more	340	Salsalate	dqjkqaajlc(vxbflrutgp) = omimtiwlgd bdypwyvbmb (dwjyhsnmbj, vkisfeufkk - hpwdlsjoxq) View more	-	12 Dec 2017
NCT00760019 (CTgov)	Phase 2/3	Atherosclerosis \| Inflammation	58	placebo+salsalate (Salsalate)	npyjfqppar(vidzhtznms) = hpxkcshgpt ppvwdhqmwl (dgwhqxooxv, kdddgxjwqt - kztolmlxlf) View more	-	06 Apr 2017
				placebo+salsalate (Placebo)	npyjfqppar(vidzhtznms) = ulchrsmway ppvwdhqmwl (dgwhqxooxv, xjlpygkspc - qfegecfafb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis